Epigenetic remodeling via HDAC6 inhibition amplifies anti-tumoral immune responses in myeloid leukemia cells

Abstract excerpt

Histone deacetylase 6 (HDAC6) has emerged as a promising therapeutic target in cancer due to its immunomodulatory effects. While its prognostic significance remains debated, we demonstrate that HDAC6 loss significantly impairs myeloid leukemia progression in vivo, despite having no functional impact on leukemia cell proliferation in vitro. Global proteome and secretome profiling of HDAC6-knockout (KO) cells reveal...

Topics

Open a Topic to create a Post that cites this publication.

• Adenosine
• B7-H1 Antigen
• Chronic Myeloid Leukemia Treatments
• Gene Expression Regulation, Leukemic
• Histone Deacetylase Inhibitors Research
• Methylation
• Peptidase Inhibition and Analysis
• Protein Degradation and Inhibitors

Identifiers and source

Literature Corpus work

8694f967-600a-5b00-ac94-69451e33e712

DOI

10.1101/2025.05.30.654805